Surgical Science Sweden AB (OTCPK:SUSRF) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Surgical Science Sweden AB Forward PE Ratio Related Terms
Surgical Science Sweden AB Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Forward PE Ratio Chart
Surgical Science Sweden AB Annual Data
Trend
2021-12
2023-12
2024-12
2025-12
Forward PE Ratio
119.05
31.35
31.79
14.35
Surgical Science Sweden AB Quarterly Data
2021-03
2021-06
2021-09
2021-12
2022-03
2022-06
2023-03
2023-09
2023-12
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
121.95
144.93
142.86
119.05
72.46
59.52
47.85
34.01
31.35
32.47
31.55
23.58
31.79
34.05
39.02
18.71
14.35
11.09
SUSRF vs VEEV, BTSG, TEM: Forward PE Ratio Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Forward PE Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Forward PE Ratio falls into.
Surgical Science Sweden AB Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Surgical Science Sweden AB (SUSRF) has a Forward PE Ratio of 17.24 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Surgical Science Sweden AB and its competitors. According to the industry distribution chart, Surgical Science Sweden AB ranks #95 out of 314 companies in the Healthcare Providers & Services industry, placing it in the top 30.3%.
Is Surgical Science Sweden AB's Forward PE Ratio too high?
Surgical Science Sweden AB's current Forward PE Ratio is 17.24. The Healthcare Providers & Services industry median Forward PE Ratio is 18.32. Surgical Science Sweden AB's value of 17.24 is 5.9% below this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #95 out of 314 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Forward PE Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #95 out of 314 companies for Forward PE Ratio. This puts Surgical Science Sweden AB in the upper half of its industry. The industry median Forward PE Ratio is 18.32. Surgical Science Sweden AB's value of 17.24 is 5.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Healthcare Providers & Services company?
The median Forward PE Ratio among Healthcare Providers & Services companies is 18.32, based on 314 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Forward PE Ratio of 17.24 is 5.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Forward PE Ratio is 18.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Forward PE Ratio is 17.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.24, compared to a current price of $4.00 — trading 71.9% below its estimated fair value. The current Forward PE Ratio is 17.24 and 5.9% below the Healthcare Providers & Services industry median of 18.32. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Forward PE Ratio is 17.24 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 71.9% below its estimated GF Value™ of $14.24.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Forward PE Ratio: 17.24
GF Value™: $14.24 vs. price of $4.00 (71.9% below fair value)
Industry Position: 5.9% below the Healthcare Providers & Services median (#95 of 314)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 